Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of BL-M08D1 for Injection in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
CTR20263292Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M08D1 in head and neck squamous cell carcinoma (HNSCC), Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
BL-M08D1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263292.